Pages that link to "Item:Q70258"
From MaRDI portal
The following pages link to Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer (Q70258):
Displayed 31 items.
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs (Q70261) (← links)
- escalation (Q133814) (← links)
- Design efficiency in dose finding studies (Q956828) (← links)
- Convergence properties of sequential Bayesian \(D\)-optimal designs (Q958799) (← links)
- Optimal Bayesian-feasible dose escalation for cancer phase I trials (Q1265963) (← links)
- Operating characteristics of the standard phase I clinical trial design. (Q1285808) (← links)
- trialr (Q1350867) (← links)
- Using a one-parameter model to sequentially estimate the root of a regression function. (Q1583204) (← links)
- An application of reinforced urn processes to determining maximum tolerated dose (Q2373664) (← links)
- Cumulative cohort design for dose-finding (Q2455719) (← links)
- Adaptive designs for selecting drug combinations based on efficacy-toxicity response (Q2475724) (← links)
- Optimal adaptive generalized Pólya urn design for multi-arm clinical trials (Q2482603) (← links)
- Theoretical study of the continual reassessment method (Q2492919) (← links)
- Adaptive designs for dose-finding based on efficacy-toxicity response (Q2492921) (← links)
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios (Q3436524) (← links)
- Designs for Single- or Multiple-Agent Phase I Trials (Q3445286) (← links)
- A Statistical Framework for Quantile Equivalence Clinical Trials with Application to Pharmacokinetic Studies that Bridge from HIV‐Infected Adults to Children (Q3549403) (← links)
- Sequential method of estimating the LD<sub>50</sub> using a modified up-and-down rule (Q4298667) (← links)
- Designs foe phase i cancer clinical trials with differentiation of graded toxicity (Q4548226) (← links)
- A Curve‐Free Method for Phase I Clinical Trials (Q4667490) (← links)
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities (Q4670477) (← links)
- Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design (Q4796210) (← links)
- SEQUENTIAL METHODS IN CLINICAL TRIALS* (Q4804482) (← links)
- Adaptive designs for binary treatment responses in phase III clinical trials: controversies and progress (Q5424121) (← links)
- Ethical considerations concerning treatment allocation in drug development trials (Q5424156) (← links)
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach (Q5427414) (← links)
- Designs for Phase I Clinical Trials with Multiple Courses of Subjects at Different Doses (Q5434918) (← links)
- Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials (Q5438331) (← links)
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach (Q5449918) (← links)
- Implementation of a Bayesian Design in a Dose‐Escalation Study of an Experimental Agent in Healthy Volunteers (Q5450494) (← links)
- Retrospective Analysis of Sequential Dose‐Finding Designs (Q5717156) (← links)